MGC Hematology Oncology-Union

Union, South Carolina 29379

2 studies enrolling now · 54 studies all time

What they study most

ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, ATM Gene Mutation, ATR Gene Mutation, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma

Studies at this site

• Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials — Recruiting now
• Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors — Recruiting now
• Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer — Recruiting now
• Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment — Running, not enrolling
• Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia — Running, not enrolling
• Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy — Running, not enrolling
• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — Running, not enrolling
• Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study — Running, not enrolling
• Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread — Running, not enrolling
• Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study — Running, not enrolling
• Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer — Running, not enrolling
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone — Stopped early
• A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources — Running, not enrolling
• T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial — Running, not enrolling
• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers — Running, not enrolling
• Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer — Running, not enrolling
• Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery — Running, not enrolling
• Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses — Running, not enrolling
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer — Running, not enrolling
• Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases — Running, not enrolling
• S0820, Adenoma and Second Primary Prevention Trial — Running, not enrolling
• Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer — Running, not enrolling
• Stepped-Care Telehealth for Distress in Cancer Survivors — Completed
• Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer — Running, not enrolling
• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer — Running, not enrolling
• Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment — Running, not enrolling
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers — Completed
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) — Running, not enrolling
• Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia — Running, not enrolling
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer — Completed
• Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma — Running, not enrolling
• Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer — Completed
• Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma — Completed
• Breast Cancer WEight Loss Study (BWEL Study) — Running, not enrolling
• Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia — Completed
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) — Completed
• Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma — Status unconfirmed
• Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery — Completed
• Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil — Completed
• Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy — Completed
• Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide — Status unconfirmed
• Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer — Completed
• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer — Completed
• Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers — Completed
• S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer — Completed
• Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer — Completed
• S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) — Completed
• Work Ability in Young Adult Cancer Survivors — Completed
• Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer — Completed
• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer — Completed